LLY-283 | B2749

LLY-283 is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50 = 22 nM). It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM).

LLY-283 is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50 = 22 nM). It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM).

B2749 | LLY-283 DataSheet

Alternate Name/Synonyms: (2R,3R,4S,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol, (R)-5′-phenyl-7-deazaadenosine; 6-amino-9-[(R)-5′-phenyl(ribofuranosyl)]-7-deazapurine,LLY283

Appearance: White to off-white solid

Formulation:

CAS Number: 2040291-27-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₇H₁₈N₄O₄

Molecular Weight: 342.35

Cell-Permeable?: TRUE

Purity: ≥98% by HPLC

Solubilities: >50 mg/ml DMSO

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: A potent and selective SAM-competitive PRMT5 inhibitor

MDL Number:

PubChem CID: 122669401

SMILES: C1=CC=C(C=C1)C(C2C(C(C(O2)N3C=CC4=C(N=CN=C43)N)O)O)O

InChi: InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)11(22)9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12+,13-,14-,17-/m1/s1

InChi Key: WWOOWAHTEXIWBO-QFRSUPTLSA-N